Claud M Grigg
Overview
Explore the profile of Claud M Grigg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
915
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burgess E, Grigg C, Boselli D, Symanowski J, Golshayan A, Graham D, et al.
Clin Genitourin Cancer
. 2025 Feb;
23(2):102302.
PMID: 39903972
Background: Androgen receptor pathway inhibitors (ARPI) in combination with docetaxel (Doc) and androgen deprivation therapy (ADT) has improved outcomes for men with metastatic hormone sensitive prostate cancer (mHSPC). We hypothesized...
2.
Burgess E, Livasy C, Symanowski J, Matulay J, Grigg C, Clark P, et al.
Urol Oncol
. 2023 Jun;
41(8):357.e23-357.e29.
PMID: 37295980
Objectives: Novel regimens targeting immune checkpoints and the cMET or HER2 pathways are under investigation in metastatic urothelial carcinoma (mUC) though co-expression of these molecular targets has not been defined....
3.
Kearns J, Matulay J, Anderson W, Hetherington T, Grigg C, Zhu J, et al.
Urol Pract
. 2023 May;
8(6):619-623.
PMID: 37145508
Introduction: 5-Alpha reductase inhibitor (5-ARI) use leads to a 50% decline in serum prostate specific antigen (PSA) without a concomitant decrease in prostate cancer (PCa) risk. We hypothesize that failure...
4.
Zhu J, Livasy C, Donahue E, Symanowski J, Grigg C, Brown L, et al.
Transl Androl Urol
. 2023 Mar;
12(2):228-240.
PMID: 36915891
Background: Galectin-1 (Gal-1) and Galectin-3 (Gal-3) are carbohydrate binding proteins with a wide range of biological activity, including regulation of cellular adhesion, proliferation, and apoptosis in solid tumors. Prior small...
5.
Burgess E, Sanders J, Livasy C, Symanowski J, Gatalica Z, Steuerwald N, et al.
Urol Oncol
. 2022 Jun;
40(8):383.e1-383.e10.
PMID: 35662501
Objectives: Small cell bladder carcinoma (SCBC) represents a rare histologic variant with a poor prognosis and for which no routine biomarkers exist. Limited reports of genomic sequencing in SCBC have...
6.
Roebuck E, Sha W, Lu C, Miller C, Burgess E, Grigg C, et al.
Urology
. 2022 Jan;
163:156-163.
PMID: 34995563
Objective: To evaluate whether racial disparities in MRI-Bx usage persisted after correction for socioeconomic, demographic, and clinical factors. Methods: This is a retrospective cohort study of patients who received either...
7.
Sanders J, Frasier C, Matulay J, Steuerwald N, Zhu J, Grigg C, et al.
Transl Androl Urol
. 2021 Aug;
10(7):2998-3009.
PMID: 34430403
Background: Intravesical bacillus Calmette-Guérin (BCG) therapy is standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) but overall efficacy is low, and no reliable predictive biomarkers currently exist to refine...
8.
Lu C, Adeyemi O, Anderson W, Hetherington T, Slawson D, Tapp H, et al.
J Urol
. 2021 Apr;
206(2):270-278.
PMID: 33793294
Purpose: Contemporary trends and racial disparities in prostate cancer screening and referral to urology for prostate cancer risk are not well characterized, despite consensus that Black men are at higher...
9.
Grigg C, Livasy C, He J, Hartman A, Clark P, Zhu J, et al.
Hum Pathol
. 2020 Oct;
107:96-103.
PMID: 33121981
Human epidermal growth factor receptor 2 (HER2) overexpression occurs in 5-10% of primary urothelial carcinomas (UCs) but has not reliably predicted benefit from HER2-targeted agents in the metastatic setting. HER2...
10.
Shu C, Gainor J, Awad M, Chiuzan C, Grigg C, Pabani A, et al.
Lancet Oncol
. 2020 May;
21(6):786-795.
PMID: 32386568
Background: Approximately 25% of all patients with non-small-cell lung cancer present with resectable stage IB-IIIA disease, and although perioperative chemotherapy is the standard of care, this treatment strategy provides only...